Printed From:

Lantus® Is Approved for Use Once a Day1

A longer peakless action profile than NPH.2

Study Design

A double-blind, randomized, crossover, euglycemic clamp study involving 20 patients with type 1 diabetes.

From Lepore and Lantus® Prescribing Information.
NPH=neutral protamine Hagedorn.

aGlucose utilization rate in mg/kg/min, determined as the amount of glucose infused to maintain constant plasma glucose levels (hourly mean values); indicative of insulin activity. Lantus® has no pronounced peak, so it mimics the steady rate of physiologic basal insulin secretion.1,2 

The median time between injection and the end of pharmacological effect was 14.5 hours for NPH and 24 hours for Lantus®. The time course of action of insulins, including Lantus®, may vary between individuals and within the same individual.


  1. Lepore M, Pampanelli S, Fanelli C, et al. Diabetes. 2000;49(12):2142-2148.
  2. Lantus® Prescribing Information. February 2015.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.